Phase 1 Study to Compare CMAB807 Injection to Prolia® in Healthy Volunteers
Status:
Completed
Trial end date:
2020-06-18
Target enrollment:
Participant gender:
Summary
CMAB807 is a human monoclonal antibody targeting the key bone resorption mediator RANKL. The
drug is administered via subcutaneous injection once six months and is approved for various
indications, including the treatment of postmenopausal women with osteoporosis at
increased/high risk of fracture. This phase 1 clincical study investigates the
pharmacokinetics, safety and immnogenicity of CMAB807,compared to prolia®, in healthy Chinese
male subjects.